Press Release
Ocular Therapeutix™ to Present New Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
Pooled safety and efficacy data for DEXENZA for the treatment of ocular pain and inflammation after ophthalmic surgery
Safety and efficacy data for DEXTENZA for the treatment of allergic conjunctivitis
Interim safety and efficacy data for OTX-TIC in subjects with glaucoma or ocular hypertension
New Preclinical Data for OTX-TIC (glaucoma), OTX-TKI (wet age-related macular degeneration), OTX-CSI (dry eye) and OTX-BPI (acute ocular pain)
"We are very excited for the planned DEXTENZA® launch.
The data being presented, pooled from three Phase 3 clinical trials,
demonstrate the benefit DEXTENZA provides in treating both ocular pain
and inflammation after cataract surgery,” commented
Poster Presentations at ARVO Annual Meeting,
-
Pharmacokinetics of OTX-CSI, a Sustained Release Cyclosporine
Intracanalicular Insert in Beagles. Vanslette A, Blizzard C,
Haberman P, Tomaszewski J, Rosales C, Metzinger JL, Goldstein MH,
Driscoll A
Sunday, April 28, 2019 ;8:00 AM –9:45 AM
West Exhibition Hall – B0424
-
Efficacy & Tolerability of OTX-TKI, a Sustained Hydrogel Delivery
System for a Tyrosine Kinase Inhibitor, in a VEGF Induced Retinal
Leakage Model: 1 Year Results. Jarrett P, ElHayek R, Kahn E, Takach
S, Metzinger JL, Goldstein MH
Sunday, April 28, 2019 ;1:00 PM –2:45 PM
West Exhibition Hall – A0249
-
Pharmacodynamic Effect and Corneal Wound Healing of OTX-BPI, a
Sustained Release Bupivacaine Intracanalicular Hydrogel Insert in
Beagle Dogs. ElHayek R, Dexter J, Bello N, Kahn E, Manning S,
Blizzard C, Driscoll A, Metzinger JL, Goldstein MH, Jarrett P
Monday, April 29, 2019 ;11:15 AM –1:00 PM
West Exhibition Hall – B0397
-
Effect of OTX-TIC, a Sustained Release Travoprost Intracameral Implant
on Central Corneal Thickness in Beagles. Driscoll A, Blizzard C,
Desai A, Langh J, Buff N, Metzinger JL, Goldstein MH, Gelormini A
Tuesday, April 30, 2019 ;11:45 AM –1:30 PM .
West Exhibition Hall – A0115
-
A Prospective, Multicenter, Open-Label First-in-Human Study to
Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (travoprost)
Implant in Subjects with Primary Open-Angle Glaucoma or Ocular
Hypertension: Preliminary Findings. Goldstein MH, Walters T,
Goldberg D, Day D, Braun E, Metzinger JL
Tuesday, April 30, 2019 ;11:45 AM –1:30 PM
West Exhibition Hall – A0130
-
Pharmacokinetics of OTX-TIC, a Sustained Release Travoprost
Intracameral Implant in Rabbits. Blizzard C, Desai A, Langh J, Buff
N, Metzinger JL, Goldstein MH, Gelormini A, Driscoll A
Tuesday, April 30, 2019 ;11:45 AM –1:30 PM
West Exhibition Hall – B0324
Abstracts and full session details can be found at www.arvo.org.
Paper Presentations at ASCRS in
-
Evaluating the Safety, Tolerability and Efficacy of OTX-TIC, a
Travoprost Intracameral Implant, in Subjects with Glaucoma. Walters
T, Day D, Goldberg D, Braun E, Metzinger JL, Goldstein MH
Sunday, May 5, 2019 ;3:42 PM –3:47 PM
SDCC – Upper Level, Room 7A
-
Management of Ocular Inflammation and Pain Following Cataract Surgery
with Dexamethasone Insert (0.4 mg). Tyson S, Bafna S, Berdahl J,
Walters T, Metzinger JL, Goldstein MH
Monday, May 6, 2019 ;8:02 AM –8:07 AM
SDCC – Upper Level, Room 1A
-
Evaluating the Safety and Efficacy of DEXTENZA, a Dexamethasone Insert
(0.4 mg) for the Treatment of Ocular Itching. McLaurin E,
Torkildsen G, Sato M, Meier E, Gomes P, Metzinger JL, Goldstein MH
Monday, May 6, 2019 ;2:11 PM –2:16 PM
SDCC – Upper Level, Room 1B
Abstracts and full session details can be found at www.ascrs.org.
Forward Looking Statements
Any statements in this press
release about future expectations, plans, and prospects for the Company,
including the commercialization of DEXTENZA, ReSure Sealant or any of
the Company’s product candidates, including the anticipated commercial
launch of, and the receipt of reimbursement codes for, DEXTENZA; the
development and regulatory status of the Company’s product candidates,
such as the Company’s regulatory submissions for and the timing and
conduct of, or implications of results from, clinical trials of DEXTENZA
for the treatment of post-surgical ocular inflammation and the prospects
for approvability of DEXTENZA for post-surgical ocular inflammation or
any other indications, OTX-TP for the treatment of primary open-angle
glaucoma and ocular hypertension, OTX-TIC for the treatment of primary
open-angle glaucoma and ocular hypertension, OTX-TKI for the treatment
of retinal diseases including wet AMD, and OTX-IVT as an
extended-delivery formulation of the VEGF trap aflibercept for the
treatment of retinal diseases including wet AMD; the Company’s
post-approval studies of ReSure Sealant and the Company’s ongoing
communications with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005271/en/
Source:
Investors
Ocular Therapeutix
Donald Notman
Chief
Financial Officer
dnotman@ocutx.com
or
Westwicke,
an ICR Company
Chris Brinzey
Managing Director
chris.brinzey@westwicke.com
Media
Ocular Therapeutix
Scott Corning
Senior Vice
President, Commercial
scorning@ocutx.com